Silibinin inhibits migration and invasion of breast cancer MDA-MB-231 cells through induction of mitochondrial fusion

Si, Lingling; Fu, Jianing; Liu, Weiwei; Hayashi, Toshihiko; Nie, Yuheng; Mizuno, Kazunori; Fujisaki, Hitomi; Onodera, Satoshi; Ikejima, Takashi

doi:10.1007/s11010-019-03640-6

Cited by 79 publications

(39 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Silymarin nanoemulsion + cold atmospheric plasma reduced intracellular ATP levels and down-regulate transcriptional and survival pathways [371]. Inhibited EMT and migration [372].…”

Section: Silymarinmentioning

confidence: 99%

“…Silibinin also inhibited cell migration and increased mitochondrial fusion, which contributed to silibinin's inhibitory effect on cell migration. Additionally, silibinin decreased ROS production, which decreased the NLRP3 inflammasome activation [372]. In silico, silymarin was shown to inhibit the proto-oncogene B-Raf (BRAF) and the smoothened gene (SMO), two targets in anticancer therapy [430].…”

Section: Silymarinmentioning

confidence: 99%

See 1 more Smart Citation

Anti-Cancer Potential of Cannabinoids, Terpenes, and Flavonoids Present in Cannabis

Tomko

Whynot

Ellis

et al. 2020

Cancers

160

139

View full text Add to dashboard Cite

In recent years, and even more since its legalization in several jurisdictions, cannabis and the endocannabinoid system have received an increasing amount of interest related to their potential exploitation in clinical settings. Cannabinoids have been suggested and shown to be effective in the treatment of various conditions. In cancer, the endocannabinoid system is altered in numerous types of tumours and can relate to cancer prognosis and disease outcome. Additionally, cannabinoids display anticancer effects in several models by suppressing the proliferation, migration and/or invasion of cancer cells, as well as tumour angiogenesis. However, the therapeutic use of cannabinoids is currently limited to the treatment of symptoms and pain associated with chemotherapy, while their potential use as cytotoxic drugs in chemotherapy still requires validation in patients. Along with cannabinoids, cannabis contains several other compounds that have also been shown to exert anti-tumorigenic actions. The potential anti-cancer effects of cannabinoids, terpenes and flavonoids, present in cannabis, are explored in this literature review.

show abstract

“…Silymarin nanoemulsion + cold atmospheric plasma reduced intracellular ATP levels and down-regulate transcriptional and survival pathways [371]. Inhibited EMT and migration [372].…”

Section: Silymarinmentioning

confidence: 99%

Section: Silymarinmentioning

confidence: 99%

Anti-Cancer Potential of Cannabinoids, Terpenes, and Flavonoids Present in Cannabis

Tomko

Whynot

Ellis

et al. 2020

Cancers

160

139

View full text Add to dashboard Cite

show abstract

“…It induces autophagy in human BC cells (102) and inhibits proliferation, migration and invasion of TNBC cells via the inhibition of the Jak2/STAT3/MMP2 signaling pathway (103). This study demonstrated that silibinin impaired mitochondrial activity and ROS generation, leading to inhibition of both the NLRP3 inflammasome pathway and CASP-1/IL-1β expression, reducing cell migration and invasion (101).…”

Section: Tnbc: An Open Challenge In Preclinical Studiesmentioning

confidence: 74%

“…A very recent "in vitro" study tested the effects of silibinin on a TNBC cell line (101). Silibinin is a natural polyphenolic flavonoid with anticancer effects.…”

Section: Tnbc: An Open Challenge In Preclinical Studiesmentioning

confidence: 99%

NLRP3 Inflammasome From Bench to Bedside: New Perspectives for Triple Negative Breast Cancer

et al. 2020

View full text Add to dashboard Cite

The tumor microenvironment (TME) is crucial in cancer onset, progression and response to treatment. It is characterized by an intricate interaction of immune cells and cytokines involved in tumor development. Among these, inflammasomes are oligomeric molecular platforms and play a key role in inflammatory response and immunity. Inflammasome activation is initiated upon triggering of pattern recognition receptors (Toll-like receptors, NOD-like receptors, and Absent in melanoma like receptors), on the surface of immune cells with the recruitment of caspase-1 by an adaptor apoptosis-associated specklike protein. This structure leads to the activation of the pro-inflammatory cytokines interleukin (IL)-1β and IL-18 and participates in different biological processes exerting its effects. To date, the Nod-Like Receptor Protein 3 (NLRP3) inflammasome has been well studied and its involvement has been established in different cancer diseases. In this review, we discuss the structure, biology and mechanisms of inflammasomes with a special focus on the specific role of NLRP3 in breast cancer (BC) and in the subgroup of triple negative BC. The NLRP3 inflammasome and its downstream pathways could be considered novel potential tumor biomarkers and could open new frontiers in BC treatment.

show abstract

“…Silibinin, an anti-cancer agent used in breast cancer patients, has been shown to suppress cancer cell migration and invasion by interfering with ROS generation and suppressing NLRP3 inflammasome activation [ 89 ]. Numerous studies have also highlighted the autophagy-modulating effects of silibinin [ 90 – 92 ]; therefore, silibinin is considered a promising therapeutic approach for various cancers.…”

Section: Introductionmentioning

confidence: 99%

Crosstalks between inflammasome and autophagy in cancer

et al. 2020

View full text Add to dashboard Cite

Both inflammasomes and autophagy have important roles in the intracellular homeostasis, inflammation, and pathology; the dysregulation of these processes is often associated with the pathogenesis of numerous cancers. In addition, they can crosstalk with each other in multifaceted ways to influence various physiological and pathological responses, including cancer. Multiple molecular mechanisms connect the autophagy pathway to inflammasome activation and, through this, may influence the outcome of pro-tumor or anti-tumor responses depending on the cancer types, microenvironment, and the disease stage. In this review, we highlight the rapidly growing literature on the various mechanisms by which autophagy interacts with the inflammasome pathway, to encourage additional applications in the context of tumors. In addition, we provide insight into the mechanisms by which pathogen modulates the autophagy-inflammasome pathway to favor the infection-induced carcinogenesis. We also explore the challenges and opportunities of using multiple small molecules/agents to target the autophagy/inflammasome axis and their effects upon cancer treatment. Finally, we discuss the emerging clinical efforts assessing the potential usefulness of targeting approaches for either autophagy or inflammasome as anticancer strategies, although it remains underexplored in terms of their crosstalks.

show abstract

Silibinin inhibits migration and invasion of breast cancer MDA-MB-231 cells through induction of mitochondrial fusion

Cited by 79 publications

References 45 publications

Anti-Cancer Potential of Cannabinoids, Terpenes, and Flavonoids Present in Cannabis

Anti-Cancer Potential of Cannabinoids, Terpenes, and Flavonoids Present in Cannabis

NLRP3 Inflammasome From Bench to Bedside: New Perspectives for Triple Negative Breast Cancer

Crosstalks between inflammasome and autophagy in cancer

Contact Info

Product

Resources

About